SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Mahalia Jackson — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientMahalia Jackson
Date of birth1911-10-26
IdentifiersMRN HR-ML035-SYN-TD; SSN (made up) 000-35-4692
Document date1964-03-09
AuthorBeatrice Fontenot, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Cardiac test results and the start of treatment. [S]

History of Present Illness

Ms. Jackson returns two weeks after the consultation with the results of her heart and eye tests. The Holter recorded first-degree atrioventricular block throughout, ectopic beats making up 6 percent of all beats, and three short runs of ventricular tachycardia, one during her palpitations. The echocardiogram and cardiac MRI show a mildly reduced pumping function (ejection fraction 47 percent) with scarring in the base of the septum and the side wall, and the FDG-PET three days ago shows active inflammation at the same sites. The eye examination was normal. Hepatitis B and C tests were negative, and she is not immune to hepatitis B. Cultures from the EBUS samples show no growth at three weeks. She is breathless on one flight of stairs, has had two more spells of palpitations, and has not fainted. She saw Dr. Asante-Miller and the cardiology team this morning. She asked whether she will sing again and was told that, with treatment, most people return to their work. She has had no thoughts of self-harm. [S]

ElementDetail
HolterPR 230 to 250 ms; ventricular ectopy 6 percent; three runs of nonsustained ventricular tachycardia up to 8 beats
Echocardiogram and MRIEjection fraction 47 percent; patchy enhancement of the basal anteroseptum and inferolateral wall
FDG-PETFocal myocardial uptake matching the MRI; active hilar and mediastinal nodes
EyesNo uveitis; normal pressures
Infection screeningHepatitis B and C negative; not immune to hepatitis B; cultures no growth at three weeks

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired; no fever or weight loss
RespiratoryPositiveBreathless on one flight of stairs; dry cough
CardiovascularPositiveTwo more spells of palpitations; no fainting, chest pain or ankle swelling
EyesNegativeNo redness or blurred vision
EndocrineNegativeNo thirst or frequent urination
PsychiatricPositiveFrightened by the heart findings, steadied by her faith; PHQ-9 7; no thoughts of self-harm

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Prednisone 20 mg oral tablet, two tablets (40 mg) by mouth each morning40 mg each morningOral route1964-03-09 to 1964-05-11completedS
Methotrexate 2.5 mg oral tablet, six tablets (15 mg) by mouth once a week on Sundays15 mg once weeklyOral route1964-03-09 to 1964-05-11completedS
Folic acid 1 mg oral tablet, one tablet by mouth dailyOne tablet dailyOral route1964-03-09activeS
Atovaquone 750 mg/5 mL oral suspension, 1500 mg (10 mL) by mouth once daily with food1500 mg once daily with foodOral route1964-03-09 to 1964-07-06completedS
Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth dailyOne tablet dailyOral route1964-03-09activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1964-03-09Body height170cmS
1964-03-09Body weight91.2kgS
1964-03-09Body mass index (BMI) [Ratio]31.6kg/m2S
1964-03-09Systolic blood pressure124mm[Hg]S
1964-03-09Diastolic blood pressure78mm[Hg]S
1964-03-09Heart rate80/minS
1964-03-09Respiratory rate18/minS
1964-03-09Body temperature36.6CelS
1964-03-09Oxygen saturation in Arterial blood by Pulse oximetry95%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1964-03-09Hemoglobin [Mass/volume] in Blood12.6g/dL12-15.5 g/dLNormalS
1964-03-09Leukocytes [#/volume] in Blood by Automated count4.810*3/uL4-11 10*3/uLNormalS
1964-03-09Lymphocytes [#/volume] in Blood by Automated count0.910*3/uL1-4.8 10*3/uLLowS
1964-03-09Platelets [#/volume] in Blood by Automated count24010*3/uL150-400 10*3/uLNormalS
1964-03-09Creatinine [Mass/volume] in Serum or Plasma1.02mg/dL0.59-1.04 mg/dLNormalS
1964-03-09Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1959)/1.73 sq M66mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1964-03-09Glucose [Mass/volume] in Serum or Plasma101mg/dL70-99 mg/dLHighS
1964-03-09Calcium [Mass/volume] in Serum or Plasma10.6mg/dL8.6-10.3 mg/dLHighS
1964-03-09Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma27U/L7-35 U/LNormalS
1964-03-09Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma29U/L8-35 U/LNormalS
1964-03-09Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma124U/L35-104 U/LHighS
1964-03-09Albumin [Mass/volume] in Serum or Plasma4g/dL3.5-5 g/dLNormalS
1964-03-09Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma240pg/mL<=125 pg/mLHighS
1964-03-09Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]7{score}S

Physical Exam

Vital signs recorded on 1964-03-09; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 91.2 kg; blood pressure 124/78, pulse 80 with occasional ectopic beats
RespiratoryClear to auscultation
CardiovascularOccasional ectopic beats; no murmur, gallop or ankle swelling; jugular venous pressure normal
MouthNo thrush; teeth in good repair
SkinNo rash or plaques
PsychiatricThoughtful; asks about her voice and travel

Problems

ProblemClinical statusVerificationCodeProvenance
Breathlessness on exertion and a dry cough for three months, worse on tour, with tiredness and chest tightness; she can no longer hold long phrases; bilateral hilar lymph node enlargement on today's chest radiograph; granulomas were reported at an abdominal operation twelve years ago, with no pathology report available: sarcoidosis must be confirmed by tissue and other causes excludedresolvedconfirmed R06.09S — Synthetic presenting problem anchored to the documented breathlessness during performances and the 1952 granulomas. Superseded by the tissue diagnosis at the consultation.
Palpitations with two spells of light-headedness while singing; ECG today: sinus rhythm with first-degree atrioventricular block (PR 240 ms) and frequent ventricular ectopic beats: cardiac involvement must be looked forresolvedconfirmed R00.2S — Synthetic finding; superseded when cardiac sarcoidosis was diagnosed.
Hypercalcemia: calcium 10.8 mg/dL with a high 1,25-dihydroxyvitamin D and a low 25-hydroxyvitamin D, while taking an over-the-counter calcium and vitamin D supplement; creatinine slightly raisedactiveconfirmed E83.52S — Synthetic finding; resolved on treatment.
Pulmonary sarcoidosis with hilar and mediastinal lymph node involvement (Scadding stage II), confirmed by non-necrotizing granulomas on EBUS-guided lymph node aspiration with negative stains and cultures; mild restriction and reduced diffusing capacity; synthetic modern detail linked to her documented sarcoidosisactiveconfirmed D86.2S — Synthetic histology, stage and lung function; her biographer reports a diagnosis of sarcoidosis after granulomas were found at an operation (D, probable).
Cardiac sarcoidosis: first-degree atrioventricular block, ventricular ectopy (6 percent of beats) with nonsustained ventricular tachycardia, left ventricular ejection fraction 47 percent, patchy late gadolinium enhancement of the basal septum and inferolateral wall, and matching focal FDG uptake on PET; synthetic modern detail linked to the documented private account that sarcoidosis was in her heartactiveconfirmed D86.85S — Synthetic cardiac findings; the account that her doctors told her sarcoidosis was in her heart rests on her biographer (D, probable), and the interpretation of her later heart disease is R.
Long-term systemic glucocorticoid treatment for sarcoidosis, with bone, glucose, blood pressure, infection and eye risks to manageactiveconfirmed Z79.52S — Synthetic treatment status.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationHolter monitoringWhen the ECG is abnormal or there are palpitationsUp to dateVentricular ectopy 6 percent; three runs of nonsustained ventricular tachycardia; first-degree block; no high-grade block
ImagingEchocardiogram and cardiac MRIWhen cardiac involvement is suspectedUp to dateEjection fraction 47 percent; late gadolinium enhancement about 9 percent of left ventricular mass
ImagingCardiac FDG-PETBefore glucocorticoids, then three to six months into treatmentUp to dateThree days ago: active myocardial inflammation matching the MRI; repeat after about five months
ExaminationEye examinationAt diagnosis, then yearlyUp to dateFive days ago: normal
LaboratoryExclusion of other granulomatous causesAt diagnosisOrderedCultures no growth at three weeks; final at six to eight weeks
LaboratoryMethotrexate safety: blood count, liver tests and creatinineBefore starting; every two to four weeks for the first three months; then every eight to twelve weeksCompleted todayBaseline: hemoglobin 12.6 g/dL, white cells 4.8, lymphocytes 0.9, platelets 240; ALT 27, AST 29, alkaline phosphatase 124 U/L, albumin 4.0 g/dL; creatinine 1.02 mg/dL, eGFR 66
LaboratoryHepatitis B and C screeningBefore immunosuppressive treatmentUp to dateNegative; not immune to hepatitis B, so vaccination starts today
LaboratorySerum calciumAt diagnosis, then at each treatment visit while it was raised or vitamin D is givenCompleted today10.6 mg/dL
LaboratoryGlucose before glucocorticoidsAt the start, then at each visitCompleted todayGlucose 101 mg/dL; A1c 5.9% at the first visit
LaboratoryNT-proBNPAt the cardiac diagnosis and when symptoms changeCompleted today240 pg/mL
ImagingBone density (DXA) and FRAXAt the start of glucocorticoids expected to last three months or moreOrderedBooked for next week
Medication safetyPneumocystis prophylaxisWhile prednisone is 20 mg or more with a second immunosuppressantCompleted todayAtovaquone started; trimethoprim-sulfamethoxazole avoided with methotrexate
Medication safetyVaccination before immunosuppressionBefore or as treatment startsCompleted todayPCV20, recombinant zoster dose 1 and hepatitis B dose 1 given today; influenza at the first visit; no live vaccines
ReferralCardiology and electrophysiologyWhen cardiac sarcoidosis is diagnosedReferredSeen with Dr. Asante-Miller today; electrophysiology study booked for next week
SurveyDepression screen (PHQ-9)At diagnosis and at each phase of treatmentCompleted todayPHQ-9 7

Goal progress:

Immunizations given today: Pneumococcal conjugate vaccine (PCV20), before immunosuppression; Recombinant zoster vaccine, dose 1 of 2; Hepatitis B vaccine (adjuvanted, two-dose series), dose 1 [S]

Guideline basis: Crouser ED, et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020;201(8):e26-e51 (PMID 32293205) (2020); Baughman RP, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J 2021;58(6):2004079 (PMID 34140301) (2021); Birnie DH, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11(7):1305-1323 (PMID 24819193) (2014); Cheng RK, et al. Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association. Circulation 2024;149(21):e1197-e1216 (PMID 38634276) (2024); Humphrey MB, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2023;75(12):2088-2102 (PMID 37845798) (2022); Singh JA, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64(5):625-639 (PMID 22473917) (methotrexate laboratory monitoring) (2012); Adult Immunization Schedule by Medical Condition and Other Indication (2026); Depression and Suicide Risk in Adults: Screening (2023)

Follow-up: Bone density next week; electrophysiology study next week. No driving for a week after any device implant. Nine-week review with lung function and blood tests. Call 911 for fainting, a sustained racing heart or a defibrillator shock. Next scheduled visit 1964-05-11: nine weeks of treatment: lung function, calcium, methotrexate safety, the new defibrillator, steroid effects, and her concert schedule. [S]